Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 10/20 | 0.33 |
| ▸ | SOAT1 | P35610 | 9/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14684504 | 0.89 | PDE4D (0.36) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL3225581 | 0.79 | PDE4D (0.38) | PDE4DALDH1A1MAPTKDM4ESMN1; SMN2 | |
| SCHEMBL3226056 | 0.78 | PDE4D (0.37) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL3216758 | 0.70 | ADORA3 (0.34) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL13851037 | 0.69 | ALDH1A1 (0.32) | ALDH1A1MEN1KMT2A | |
| SCHEMBL3222801 | 0.69 | PDE4D (0.41) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL3219443 | 0.66 | PLAT (0.43) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL2967367 | 0.65 | PDE4D (0.38) | PDE4DDGAT1SOAT1ALDH1A1MAPT | |
| SCHEMBL2170335 | 0.63 | PDE4D (0.42) | PDE4DALDH1A1MAPTHTTMEN1 | |
| SCHEMBL21818438 | 0.61 | CA12 (0.43) | PDE4DDGAT1SOAT1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-24 | — | — | US | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
| EP-2060572-A1 | PYRAZOLOPYRIDINE DERIVATIVE AND PHOSPHODIESTERASE (PDE) INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2009-05-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318385-A1 | Pyrazolopyride derivative and phosphodiesterase ( pde) inhibitors containing the same as active ingredient | PDE3A, PDE5A, PDE3B | PDE4D 16/4885DGAT1 3704/4885SOAT1 3683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.